Department of Mathematics and Statistics, The College of New Jersey, 2000 Pennington Road, P.O. Box 7718, Ewing, NJ 08628-0718, USA
Copyright © 2011 Jana L. Gevertz. This is an open access article distributed under the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Mathematical modeling techniques have been widely employed to understand how cancer
grows, and, more recently, such approaches have been used to understand how cancer can
be controlled. In this manuscript, a previously validated hybrid cellular automaton model
of tumor growth in a vascularized environment is used to study the antitumor activity
of several vascular-targeting compounds of known efficacy. In particular, this model is used
to test the antitumor activity of a clinically used angiogenesis inhibitor (both in isolation,
and with a cytotoxic chemotherapeutic) and a vascular disrupting agent currently undergoing
clinical trial testing. I demonstrate that the mathematical model can make predictions in
agreement with preclinical/clinical data and can also be used to gain more insight into these
treatment protocols. The results presented herein suggest that vascular-targeting agents, as
currently administered, cannot lead to cancer eradication, although a highly efficacious agent
may lead to long-term cancer control.